

# THE FUTURE OF EYE CARE

## Rose Bengal & Photodynamic Therapy

Revolutionary Treatments for Infectious  
Keratitis and Other Eye Diseases

Copyright © 2026 VisiRose, Inc.





# Forward-Looking Statements

VisiRose, Inc. (VisiRose) is a majority-owned subsidiary of Provectus Biopharmaceuticals, Inc. (Provectus), a publicly-traded company (OTCQB: PVCT).

The information in this presentation may include “forward-looking statements” within the meaning of U.S. federal securities legislation and relating to the business of VisiRose, its partners, and its affiliates that are based on the opinions and estimates of company management and are subject to a variety of risks, uncertainties, and other factors, which could cause actual events or results to differ materially from those projected in these forward-looking statements.

Forward-looking statements are often, but not always, identified using words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook. The safety and efficacy of drug agents and candidates and/or therapeutic uses under investigation by VisiRose have not been established.

There is no guarantee these agents, candidates, and/or uses will receive health authority approval or become commercially available in any country or such candidates as products will achieve any revenue levels. Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on them.

Forward-looking statements contained in this presentation are made as of the date hereof or as of the date specifically specified herein. VisiRose undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable federal securities laws. Forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in Provectus’s filings with the U.S. Securities and Exchange Commission, including those described in Item 1A of its Annual Report on Form 10-K for the period ended December 31, 2024 and Quarterly Report on Form 10-Q for the period ended September 30, 2025.




## About VisiRose

Vision is humanity's most treasured sense.

Yet for countless people worldwide, the scourge of eye infection and disease has stolen this precious faculty of sight, cloaking them in shadows, discomfort, and often perpetual darkness.

Through invention, science, and technology, VisiRose is committed to reclaiming what has been lost, offering the transformative gift of renewed sight.

VisiRose is a clinical-stage biotechnology company of the University of Miami and Provectus Biopharmaceuticals, focused on commercializing the Miller School of Medicine's Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center's innovative ocular research using bioactive synthetic small molecule rose bengal.





# Innovation and Clinical Validation Lie at the Core of VisiRose

**#1 in Ophthalmology**



**#1 for the 24<sup>th</sup> time**  
2025-2026 U.S. News & World Report Best  
Hospitals Ranking

**Translational Vision  
Research Center**



**Bascom Palmer Eye Institute**

**Pharmaceutical-Grade  
Rose Bengal API**



**Independent Validation,  
Global Reach & Impact**





# Infectious Keratitis: A Growing Global Threat

*Leading cause of corneal blindness and vision impairment<sup>1</sup>*

**5-10M**

People affected globally  
each year<sup>1</sup>


**50-100K**

Americans affected  
every year<sup>1,2</sup>

## Increasing incidence<sup>3</sup>

- Limitations of SOC's
- Poor eye hygiene
- Contact lens wear
- Environmental conditions
- Multidrug resistance

**Marginalized populations suffer** in the U.S. and the rest of the world, having no effective solutions



## Pathogenic Sources

Bacterial, Fungal, Viral, and  
Parasitic





### Broad-Spectrum Efficacy

Active against multiple types and strains of pathogens



### Non-Invasive Treatment

Easy to administer, avoiding the need for surgery



### Rapid Complete Resolution

Faster, better outcomes compared to SOC's



### Cost Effectiveness

Lower direct and indirect medical treatment costs



# Introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT)


Developed at the Ophthalmic Biophysics Center of Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine over 10+ years

- Innovative therapy for acute treatment, leveraging the inherent anti-pathogenic properties of synthetic small molecule Rose Bengal and green light activation
- Clinically validated by ophthalmic medical centers in the U.S., India, Brazil, and Mexico in 500+ patients to date
- Non-clinical research and clinical data published and presented in 50+ peer-reviewed journals and medical conferences by Bascom Palmer and other centers
- Multi-Modal Mechanism of Action
  - Reactive Oxygen Species: Rose bengal-generated ROS damages microbial cells (cell membranes, proteins, DNA) and leads to their death
  - Immune modulation: Rose bengal may induce anti-microbial peptides in eye epithelial cells, leading to pro- and anti-inflammatory modulation of innate and adaptive immune signaling pathways and responses





# Global Ophthalmic Market Opportunity for Rose Bengal-based Therapies



**\$20+ billion**

Global ophthalmic market for rose bengal-based therapies



Significant opportunities from keratitis, keratoconus, and other diseases and disorders of the eye

## Competitive Landscape

***Infectious keratitis.*** Superior activity compared to existing medicines and novel treatments (e.g., riboflavin PDT)

## Target Segments

- Rising concerns of antimicrobial resistance: U.S., Europe
- High-incidence: Asia, Latin America, Africa

## Other Indications

- Infectious scleritis<sup>1</sup>
- Corneal ectasia<sup>2</sup>
- Keratoconus<sup>2</sup>
- Floppy eyelid syndrome<sup>2</sup>



# Leadership Team

## Ed Pershing, CPA Chairman of the Board

- CEO and Chairman of Provectus Biopharmaceuticals; Previously CEO and co-founder of Pershing Yoakley & Associates (PYA), a top 20 healthcare consulting and top 100 accounting firm in the U.S.
- Other healthcare-focused companies: Healthcare Horizons Consulting Group, Realty Trust Group, PYA Waltman Capital, PYA Data Analytics
- Community-Based Not-For-Profit Organizations: Knoxville Area Project Access (KAPA), Maternity Center of East Tennessee, Tennessee Health Partnership (THP)

## Dominic Rodrigues Acting CEO; Director

- President and Vice Chairman of Provectus; Previously worked in management consulting and corporate development in science and technology-driven industries
- Finance professor at the University of Nevada, Las Vegas; Venture capitalist at defense contractor SAIC; Currency derivatives trader at Bank of Montreal; Project manager and engineer at Jacques Whitford

## Heather Raines, CPA Acting CFO

- CFO of Provectus; Previously VP of Finance for BDry Waterproofing and AMT Business Unit Controller at AMETEK (NYSE: AME)
- Tax analyst at Goody's Family Clothing; Accounting Manager at Siemens Medical Solutions USA, a wholly owned subsidiary of Siemens AG (NYSE: SI), and CTI Molecular Imaging (Nasdaq: CTMI)

## John Lacey, III, M.D. Director

- Former Chief Medical Officer and Senior Vice President of University Health System d/b/a University of Tennessee Medical Center (UTMC)
- Internal medicine practitioner for ~40 years
- Helped create KAPA

## Webster Bailey Director

- Executive Director of Metro Drug Coalition
- Previously 15-year career working in a residential addiction treatment center setting
- Winner of multiple awards and accolades for substance abuse prevention initiatives

### KEY COLLABORATOR



### PROSPECTIVE COLLABORATORS





### **Strong Market Potential**

Global addressable patient markets with significant unmet need

### **Innovative Solution**

Directly addresses critical clinical challenges

### **Clinically Validated**

Backed by independent, consistent, global multi-center data

### **Scalable Business Model**

Clear path to adoption, growth, profitability, and global accessibility

### **VisiRose, Inc.**

800 S. Gay Street, Suite 1610  
Knoxville, TN 37929 USA

### **Investor Relations & Media**

[contact@visirose.com](mailto:contact@visirose.com)